Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note

Company Performance - Moderna's stock closed at $26.25, reflecting a -1.83% change from the previous day, underperforming the S&P 500's daily loss of 0.16% [1] - Over the past month, Moderna's stock has increased by 11.98%, outperforming the Medical sector's gain of 1.54% and the S&P 500's gain of 1.14% [1] Earnings Forecast - The upcoming earnings report for Moderna is expected to show an EPS of -$1.99, representing a significant 6733.33% decline from the same quarter last year [2] - Revenue is forecasted to be $861.08 million, indicating a 53.76% decrease compared to the same quarter of the previous year [2] - For the full year, earnings are projected at -$9.62 per share and revenue at $1.88 billion, reflecting changes of -8.46% and -41.8% respectively from the prior year [3] Analyst Revisions - Recent revisions to analyst forecasts for Moderna are crucial as they reflect short-term business trends, with upward revisions indicating analyst optimism regarding the company's profitability [4] - The Zacks Rank system, which incorporates estimate changes, has a strong track record of outperforming, with stocks rated 1 producing an average annual return of +25% since 1988 [6] Industry Context - The Medical - Biomedical and Genetics industry, part of the Medical sector, currently holds a Zacks Industry Rank of 94, placing it in the top 39% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]